Sci PharmtechTPE:4119 -0.56%67 Interest Coverage is 23.65 as of Dec. 2025, which is 98% below its 10-year median of 1,026.36. GuruFocus rates TPE:4119 with a GF Score™ of 67/100 and a GF Value™ of NT$96.43 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 684 Drug Manufacturers companies, Sci Pharmtech ranks better than 65.5% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Sci Pharmtech's
Operating Income
for the
three
months ended in Dec. 2025 was NT$43 Mil. Sci Pharmtech's Interest Expense for the
three
months ended in Dec. 2025 was NT$-2 Mil.
Sci Pharmtech's interest coverage for the quarter that ended in Dec. 2025 was 23.65.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Sci Pharmtech's Interest Coverage or its related term are showing as below:
TPE:4119'
s Interest Coverage Range Over the Past 10 Years
Min: 25.48 Med: 1026.36 Max: 258372.5
Current: 31.45
TPE:4119's Interest Coverage is ranked better than 65.5% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs TPE:4119: 31.45
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Sci Pharmtech Interest Coverage Related Terms
Sci Pharmtech Interest Coverage Historical Data
* Premium members only.
The historical data trend for Sci Pharmtech's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TPE:4119 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sci Pharmtech (TPE:4119) has a Interest Coverage of 23.65 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sci Pharmtech and its competitors. This is 98% below median its historical median of 1,026.36. Over the past decade, Sci Pharmtech's Interest Coverage has ranged from 25.48 to 258,372.50. According to the industry distribution chart, Sci Pharmtech ranks #236 out of 684 companies in the Drug Manufacturers industry, placing it in the top 34.5%.
Is Sci Pharmtech's Interest Coverage too high?
Sci Pharmtech's current Interest Coverage of 23.65 is 98% below median its 10-year median of 1,026.36. Over the past 10 years, this metric has ranged from a low of 25.48 to a high of 258,372.50. The Drug Manufacturers industry median Interest Coverage is 12.77. Sci Pharmtech's value of 23.65 is 85.3% above this industry median. Based on the distribution chart, Sci Pharmtech ranks #236 out of 684 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sci Pharmtech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #236 out of 684 companies for Interest Coverage. This puts Sci Pharmtech in the upper half of its industry. The industry median Interest Coverage is 12.77. Sci Pharmtech's value of 23.65 is 85.3% above this benchmark. Historically, Sci Pharmtech's own Interest Coverage has ranged from 25.48 to 258,372.50 over the past decade. While the company's 10-year median is 1,026.36 vs. the industry median of 12.77, Sci Pharmtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sci Pharmtech's current Interest Coverage of 23.65 is 85.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sci Pharmtech and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current Interest Coverage is 23.65, which is 98% below median its own 10-year median of 1,026.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$96.43, compared to a current price of NT$44.25 — trading 54.1% below its estimated fair value. The current Interest Coverage is 23.65, which is 98% below median its 10-year median of 1,026.36 and 85.3% above the Drug Manufacturers industry median of 12.77. Sci Pharmtech's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current Interest Coverage is 23.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$44.25 is trading 54.1% below its estimated GF Value™ of NT$96.43.
GuruFocus considers Sci Pharmtech to be Possible Value Trap.
Key valuation signals for TPE:4119:
Interest Coverage: 23.65 (98% below median its 10-year median of 1,026.36)
GF Value™: NT$96.43 vs. price of NT$44.25 (54.1% below fair value)
Industry Position: 85.3% above the Drug Manufacturers median (#236 of 684)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
67GF Score
Get the complete analysis for TPE:4119
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
